Format

Send to

Choose Destination
See comment in PubMed Commons below
J Thorac Oncol. 2014 Sep;9(9):1332-9. doi: 10.1097/JTO.0000000000000257.

Safety and effectiveness of bevacizumab-containing treatment for non-small-cell lung cancer: final results of the ARIES observational cohort study.

Author information

  • 1*Yale Cancer Center and Smilow Cancer Hospital, New Haven, Connecticut; †Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, Tennessee; ‡Department of Oncology, Johns Hopkins Medical School, Baltimore, Maryland; §Oncology Associates of Bridgeport, PC, Trumbull, Connecticut; ‖Duke University Health Systems, Durham, North Carolina; ¶The University of Miami Sylvester Cancer Center, Deerfield Beach, Florida; #University of Minnesota, Minneapolis, Minnesota; **National Lung Cancer Partnership, Madison, Wisconsin; ††Karmanos Cancer Institute, Detroit, Michigan; ‡‡Genentech, Inc., South San Francisco, California; and §§Scripps Clinic, La Jolla, California.

Abstract

INTRODUCTION:

Bevacizumab, a recombinant humanized monoclonal antibody against vascular endothelial growth factor, was approved by the US Food and Drug Administration for the treatment of advanced non-small-cell lung cancer (NSCLC) in combination with carboplatin and paclitaxel. ARIES (Avastin Regimens: Investigation of Effectiveness and Safety), a prospective observational cohort study, evaluated outcomes in a large, community-based population of patients with first-line NSCLC.

METHODS:

From 2006 to 2009, ARIES enrolled patients with locally advanced or metastatic NSCLC who were eligible for bevacizumab, excluding those with predominantly squamous histology. Patients were required to provide informed consent and to have initiated bevacizumab with chemotherapy within 4 months before enrollment. There were no protocol-defined treatments or assessments. The dosing of bevacizumab and chemotherapy, and the choice of chemotherapy regimen, was at the discretion of the treating physician.

RESULTS:

ARIES enrolled 1967 patients with first-line NSCLC. At study closure, median follow-up was 12.5 months (range, 0.2-65.5). Median age was 65 years (range, 31-93), and 252 patients (12.8%) identified as never smokers. Median progression-free survival was 6.6 months (95% confidence interval, 6.3-6.9), and median overall survival was 13.0 months (95% confidence interval, 12.2-13.8) with first-line bevacizumab plus chemotherapy. Incidences of bevacizumab-associated adverse events (19.7% overall) were consistent with those in randomized controlled trials of bevacizumab in NSCLC.

CONCLUSION:

Results from ARIES demonstrate similar outcomes to randomized controlled trials of bevacizumab when added to standard chemotherapy in a real-world patient population with advanced NSCLC.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT00388206.

PMID:
25122429
DOI:
10.1097/JTO.0000000000000257
[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center